Clinical Trial Update: Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) [Phase 1]

View source ↗

Summary

A Phase 1 trial update reporting on treatment duration increments and pharmacodynamic assessments of CX-4945 in basal cell carcinoma, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Silmitasertib (CX-4945) (silmitasertib)

Snippet

Sponsor: Senhwa Biosciences, Inc. | Conditions: Carcinoma, Basal Cell | Phase 1 | Status: COMPLETED | Results posted: 2025-05-20